Symposium

MediWound Reports First Quarter 2024 Financial Results and Provides Company Update

Retrieved on: 
水曜日, 5月 29, 2024
Wound, Patient, GMP, Research and development, Hospital, Burn, Tax, European Wound Management Association, Eastern Time Zone, Food, Supplement, SAWC, CAPEX, HERE, Exercise, FDA, Therapy, Bank statement, Expanded access, Forecasting, EWMA, Event, WHS, Depreciation, Operating cost, Symposium, BLA, Research, Table, Adjustment, NEXT, Bromelain (pharmacology), Pharmaceutical industry

Revenue: Revenue for the first quarter of 2024 was $5.0 million, compared to $3.8 million in the first quarter of 2023.

Key Points: 
  • Revenue: Revenue for the first quarter of 2024 was $5.0 million, compared to $3.8 million in the first quarter of 2023.
  • Research and Development: R&D expenses in the first quarter of 2024 were $1.5 million, compared to $2.1 million in the first quarter of 2023.
  • Operating Results: Operating loss in the first quarter of 2024 was $3.7 million, compared to an operating loss of $4.4 million in the first quarter of 2023.
  • During the first quarter of 2024, the Company received $0.5 million from the exercise of Series A warrants.

D&H Canada Launches “Partnerfi” Community Delivering Collaboration, Resources and Growth Opportunities

Retrieved on: 
火曜日, 5月 21, 2024
UC, Marketing, Element, As a service, D&H, AI, Symposium, MSP, Management

MISSISSAUGA, Ontario, May 21, 2024 (GLOBE NEWSWIRE) -- D&H Canada, a leading provider of technology solutions to the North American channel, announces it is launching its peer-to-peer partner engagement community offerings in Canada, creating a comprehensive partner organization called D&H Canada Partnerfi community. Partnerfi members will receive exclusive advantages such as an enhanced “SuccessPath Premier” enablement program, discounts, incentives, access to subject-matter experts and keynote panelists from the field, exclusive member pricing on D&H Canada services, enhanced credit offerings, best practices development, leadership development, peer networking opportunities, and more. Partnerfi’s official launch was May 1, 2024, and its first Partnerfi Symposium took place May 6 to 9. The program is designed to serve a core network of D&H’s VAR and MSP partners.

Key Points: 
  • The D&H Canada Partnerfi Community initially includes approximately 50 core partners, and will continue to build in scope over the course of D&H’s Fiscal Year 2025 (which began May 1).
  • The Partnerfi Community will meet for approximately two multi-day, live Symposium events per year, in addition to other virtual networking opportunities throughout the year.
  • Members will also be privy to peer networking opportunities to help them develop best practices; plus networking opportunities with D&H leadership.
  • “We’re thrilled to implement D&H’s Partnerfi Community in Canada, providing valuable training, tools, and access to industry experts for members.

MolecuLight Clinical Research Featured at the Upcoming SAWC Spring 2024 Conference

Retrieved on: 
火曜日, 5月 14, 2024
Patient, DX, Fluorescence imaging, Exhibition, Evaluation, General number field sieve, CLASS, SAWC, Education, Pyoderma, FDA, Effectiveness, Publication, Infection, Antibiotic, Madigan Army Medical Center, Symposium, ASC, Pyoderma gangrenosum, Fluorescence, Medical imaging

Notably, one of these posters, recognized as the top-scoring abstract, introduces an innovative upcoming device feature: thermal imaging.

Key Points: 
  • Notably, one of these posters, recognized as the top-scoring abstract, introduces an innovative upcoming device feature: thermal imaging.
  • The international conference, taking place from May 14 - 18, 2024, in Orlando, Florida, stands as one of the largest multidisciplinary meetings of wound care professionals globally.
  • In addition to the clinical posters and presentations at SAWC Spring 2024 , the MolecuLight i:X® and DX™ imaging devices will be available for demonstration in the MolecuLight booth #312 in the Exhibition Hall.
  • With unmatched clinical evidence including 95 peer-reviewed publications with over 3000 patients, they are used by leading wound care facilities globally.

MolecuLight Clinical Research Featured at the Upcoming SAWC Spring 2024 Conference

Retrieved on: 
火曜日, 5月 14, 2024
Patient, DX, Fluorescence imaging, Exhibition, Evaluation, General number field sieve, CLASS, SAWC, Education, Pyoderma, FDA, Effectiveness, Publication, Infection, Antibiotic, Madigan Army Medical Center, Symposium, ASC, Pyoderma gangrenosum, Fluorescence, Medical imaging

TORONTO and ORLANDO, Fla., May 14, 2024 /PRNewswire/ -- - MolecuLight Inc., the pioneer in point-of-care fluorescence imaging for real-time detection of elevated bacterial loads in wounds, proudly announces the presentation of findings from multiple MolecuLight studies in nine clinical posters at the Symposium on Advanced Wound Care (SAWC) Spring 2024. These studies feature new data demonstrating enhanced diagnostics, targeted debridement, improved healing outcomes, and increased patient engagement facilitated by MolecuLight devices. Notably, one of these posters, recognized as the top-scoring abstract, introduces an innovative upcoming device feature: thermal imaging. The international conference, taking place from May 14 - 18, 2024, in Orlando, Florida, stands as one of the largest multidisciplinary meetings of wound care professionals globally.

Key Points: 
  • Notably, one of these posters, recognized as the top-scoring abstract, introduces an innovative upcoming device feature: thermal imaging.
  • The international conference, taking place from May 14 - 18, 2024, in Orlando, Florida, stands as one of the largest multidisciplinary meetings of wound care professionals globally.
  • In addition to the clinical posters and presentations at SAWC Spring 2024 , the MolecuLight i:X® and DX™ imaging devices will be available for demonstration in the MolecuLight booth #312 in the Exhibition Hall.
  • With unmatched clinical evidence including 95 peer-reviewed publications with over 3000 patients, they are used by leading wound care facilities globally.

New measures to support the well-being of Veterans and their families through Budget 2024

Retrieved on: 
月曜日, 5月 13, 2024
Well, Knowledge, Employment, Organization, AB, Fund, University, Health, Research, Veterans' affairs, University of Alberta, Symposium, Woman, National security, Veterans Affairs Canada, VAC, Government, Quality of life, Real estate

A portion of these funds will be allocated to organizations and initiatives that support Veterans' health and employment, as well as women, Indigenous, and 2SLGBTQI+ Veterans.

Key Points: 
  • A portion of these funds will be allocated to organizations and initiatives that support Veterans' health and employment, as well as women, Indigenous, and 2SLGBTQI+ Veterans.
  • In 2022, the CMVFC3 received funding through the Veteran and Family Well-being Fund to support the academic and employment success of Veteran students and their families.
  • Through Budget 2024, we reaffirm our commitment to working with our partners to meet the needs of Canada's Veterans and their families."
  • Since 2015, the Government of Canada has invested over $11.5 billion to support Veterans.

SmartTRAK Launches New Site-of-Care Treatment Tracker for Wound Care Powered by Data Partnership with Intellicure Analytics

Retrieved on: 
月曜日, 5月 13, 2024
Partnership, SAWC, History, Regenerative medicine, Symposium, GM, Consultant, Nursing

IRVINE, Calif., May 13, 2024 /PRNewswire-PRWeb/ -- SmartTRAK, the leading Medtech market and business intelligence solution in Orthopedics, Wound Care, Regenerative Medicine and Neuro Therapies, in partnership with Intellicure Analytics announces the release of SmartTRAK Treatment Tracker, an innovative tool that provides in-depth market data and trending analytics across wound care treatments by site of care. The first offering in the data solutions portfolio is available now and covers the usage of Skin Substitutes in the hospital outpatient department (HOPD).

Key Points: 
  • New offering delivers wound care companies with actionable data and analytics on wound care treatments, products and brands by site of care.
  • IRVINE, Calif., May 13, 2024 /PRNewswire-PRWeb/ -- SmartTRAK, the leading Medtech market and business intelligence solution in Orthopedics, Wound Care, Regenerative Medicine and Neuro Therapies, in partnership with Intellicure Analytics announces the release of SmartTRAK Treatment Tracker , an innovative tool that provides in-depth market data and trending analytics across wound care treatments by site of care.
  • "Wound care companies are in need of organized, easily accessible insights related to wound care treatments by site of care to drive their growth strategies," says Susan Paquette, VP/GM of SmartTRAK Wound Care.
  • "Wound care companies are in need of organized, easily accessible insights related to wound care treatments by site of care to drive their growth strategies," says Susan Paquette, VP/GM of SmartTRAK Wound Care.

ShareInvestor celebrates 25th anniversary; Holding company rebrands as AlphaInvest

Retrieved on: 
木曜日, 4月 11, 2024
ACRA, Senior management, Social media, Accounting, Symposium, Non-fungible token, Generation Z, SPH, PTSI, Face, Consultant, Singapore Press Holdings, Calendar, Security (finance)

Ltd., the holding company of Singapore's largest independent platform for retail investors, today announced a name change and a new logo to mark its 25th anniversary.

Key Points: 
  • Ltd., the holding company of Singapore's largest independent platform for retail investors, today announced a name change and a new logo to mark its 25th anniversary.
  • The new holding company identity coincides with the Group's 25th anniversary of its founding in 1999.
  • The Group's holding company has been registered with the Accounting and Corporate Regularity Authority (ACRA) as "AlphaInvest Holdings Pte.
  • AlphaInvest is currently the organiser of several prominent events on the annual investing calendar such as InvestFair and the REITs Symposium.

Arch Therapeutics to Present AC5® Advanced Wound System at the 2024 Symposium on Advanced Wound Care Spring Meeting (SAWC Spring)

Retrieved on: 
月曜日, 5月 6, 2024
Chin Na, OTCQB, Food, Symposium, AC5, Patient, SAWC, Human, Wound healing, Therapy, Orlando World Center Marriott, User experience, Nursing

FRAMINGHAM, Mass., May 06, 2024 (GLOBE NEWSWIRE) -- Arch Therapeutics, Inc. (OTCQB: ARTH) (“Arch” or the “Company”), a marketer and developer of novel self-assembling wound care and biosurgical products, today announced that the Company’s first commercial product, AC5® Advanced Wound System (“AC5”), will be featured at the 2024 Symposium on Advanced Wound Care Spring Meeting (“SAWC Spring”), which takes place at Orlando Marriott World Center, Orlando, from May 14-18, 2024.

Key Points: 
  • FRAMINGHAM, Mass., May 06, 2024 (GLOBE NEWSWIRE) -- Arch Therapeutics, Inc. (OTCQB: ARTH) (“Arch” or the “Company”), a marketer and developer of novel self-assembling wound care and biosurgical products, today announced that the Company’s first commercial product, AC5® Advanced Wound System (“AC5”), will be featured at the 2024 Symposium on Advanced Wound Care Spring Meeting (“SAWC Spring”), which takes place at Orlando Marriott World Center, Orlando, from May 14-18, 2024.
  • Arch’s team will be available for discussions with clinicians throughout the Symposium and at Arch’s booth (#535) in the exhibit hall.
  • Terrence W. Norchi, MD, President and CEO of Arch Therapeutics, said, “We are delighted that AC5 Advanced Wound System will be presented again at this important Symposium.
  • AC5 is a synthetic self-assembling wound care product that provides clinicians with multi-modal support and utility across all phases of wound healing.

Dyno Therapeutics Unveils Path to Exponentially Reducing the Cost of In Vivo Gene Delivery at the 2024 American Society of Gene & Cell Therapy (ASGCT) Annual Meeting

Retrieved on: 
木曜日, 5月 9, 2024
Software, Research, General Health, Pharmaceutical, Technology, Artificial Intelligence, Genetics, Health Technology, Science, Biotechnology, Other Science, Health, Brain, Ecosystem, LEAP, Dyno, Symposium, Cell, AAV, Intelligence, Engineering, Human, DNA, Patient, Wrist, Gene, Eye, Society, NVIDIA, Annual general meeting, Therapy, Vaccine

The Scientific Symposium showcased Dyno’s approach to applying artificial intelligence to engineering novel adeno-associated virus (AAV) capsids for optimized in vivo delivery.

Key Points: 
  • The Scientific Symposium showcased Dyno’s approach to applying artificial intelligence to engineering novel adeno-associated virus (AAV) capsids for optimized in vivo delivery.
  • These results demonstrate the potential of these AI methods to broaden the number of patients who can benefit from gene therapy using synthetic capsids for gene delivery.
  • The work will help advance design capabilities for gene therapies and other sequence-based medicines with potential for transformative patient impact.
  • The collaboration will focus on scaling Dyno’s pioneering “lab-in-the-loop” sequence design approach using NVIDIA’s optimized cloud and BioNeMo platforms.

The Modern Data Company Chosen as Finalist for the 2024 MIT Sloan CIO Symposium’s Innovation Showcase

Retrieved on: 
火曜日, 5月 7, 2024
Professional Services, Data Management, Technology, Data Analytics, Software, Artificial Intelligence, Organizational founder, Multimedia, Enterprise, Symposium

The Modern Data Company, a leader in data product lifecycle management and the inventor of the world’s first data operating system, DataOS®, today announced its selection as a finalist in the 2024 Innovation Showcase at the 21st annual MIT Sloan CIO Symposium.

Key Points: 
  • The Modern Data Company, a leader in data product lifecycle management and the inventor of the world’s first data operating system, DataOS®, today announced its selection as a finalist in the 2024 Innovation Showcase at the 21st annual MIT Sloan CIO Symposium.
  • View the full release here: https://www.businesswire.com/news/home/20240507194077/en/
    This prestigious selection recognizes The Modern Data Company as a leading innovator in the Enterprise IT sector.
  • Among ten early-stage companies chosen, The Modern Data Company stands out for its groundbreaking data management solutions that deliver tangible value to businesses.
  • “We are thrilled to be selected as a finalist for the MIT Sloan CIO Symposium’s Innovation Showcase,” said Srujan Akula, CEO and Cofounder of The Modern Data Company.